Pharmyang的个人主页 - 老虎社区

Pharmyang

药物研发专业，对美国医药股感兴趣

IP属地：未知

63关注

233粉丝

3主题

0勋章

2022-01-18

‌$Rivian Automotive, Inc.(RIVN)$‌上周买了82的put，1.21到期，希望它继续跌，弥补我在 $Tesla$ call 上的损失

2021-05-04

$Atea Pharmaceuticals, Inc.(AVIR)$Merck宣布免费授权给印度它的抗病毒药，对ATEA是一大利空。另外，好像流通股变多了很多。

2019-10-10

$Sangamo BioSciences(SGMO)$ 这货最近持续下跌，投资人不看好

2019-01-28

$Sangamo BioSciences(SGMO)$估计二月份的报告会出些好结果，估计能涨涨

2018-07-16

$CRISPR Therapeutics AG(CRSP)$ crispr遭遇巨大挑战，短期内看空

2018-06-28

最近老虎行情刷新特别慢，个股新闻推送还停留在五月份。是我系统的问题吗?大家最近体验如何?

2018-04-09

分析的好

@科迪勒拉:CNAT：道阻且长行则将至

2018-02-16

$Eyenovia Inc.(EYEN)$这股成交量可真惨淡

2017-11-27

这股最近强势反弹，看来有翻身的机会了

$Northwest Biotherapeutics(NWBO)$这股最近强势反弹，看来有翻身的机会了

这股最近强势反弹，看来有翻身的机会了

2017-09-28

看好产品线，应该会涨起来

$Deciphera Pharmaceuticals Inc.(DCPH)$新股发行第一帖，果断入手1000股，早晚能涨起来

看好产品线，应该会涨起来

2017-08-23

有收购传闻，要上吗？

$Paratek Pharmaceuticals Inc.(PRTK)$盘前暴涨

有收购传闻，要上吗？

2017-07-28

$德纳维制药(DVAX)$乙肝疫苗终于被认可了，投票11:1 推荐，果断买入，15.7-16.0入手，下周开盘还会继续大涨

2017-07-26

$Intellipharmaceutics Internation(IPCI)$FDA拒了

2017-07-20

$Kala Pharmaceuticals Inc.(KALA)$继续打新股，好的公司打新还是相当安全的

2017-07-14

$Portola Pharmaceuticals Inc.(PTLA)$这股自从拿到批件暴涨后还在慢慢涨，长期看好啊

2017-07-07

$Pieris Pharmaceuticals, Inc.(PIRS)$ 趋势不错，长期看好

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3461771638976755","uuid":"3461771638976755","gmtCreate":1498677681581,"gmtModify":1498753032512,"name":"Pharmyang","pinyin":"pharmyang","introduction":"","introductionEn":null,"signature":"药物研发专业，对美国医药股感兴趣","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":233,"headSize":63,"tweetSize":18,"questionSize":0,"limitLevel":900,"accountStatus":3,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":3,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":64,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-4","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"明星虎友","description":"加入老虎社区2000天","bigImgUrl":"https://static.tigerbbs.com/dddf24b906c7011de2617d4fb3f76987","smallImgUrl":"https://static.tigerbbs.com/53d58ad32c97254c6f74db8b97e6ec49","grayImgUrl":"https://static.tigerbbs.com/6304700d92ad91c7a33e2e92ec32ecc1","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001}],"userBadgeCount":1,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":697545586,"gmtCreate":1642543473616,"gmtModify":1642543473616,"author":{"id":"3461771638976755","authorId":"3461771638976755","name":"Pharmyang","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3461771638976755","authorIdStr":"3461771638976755"},"themes":[],"htmlText":"‌<a href=\"https://laohu8.com/S/RIVN\">$Rivian Automotive, Inc.(RIVN)$</a>‌上周买了82的put，1.21到期，希望它继续跌，弥补我在 $Tesla$&nbsp;call 上的损失","listText":"‌<a href=\"https://laohu8.com/S/RIVN\">$Rivian Automotive, Inc.(RIVN)$</a>‌上周买了82的put，1.21到期，希望它继续跌，弥补我在 $Tesla$&nbsp;call 上的损失","text":"‌$Rivian Automotive, Inc.(RIVN)$‌上周买了82的put，1.21到期，希望它继续跌，弥补我在 $Tesla$ call 上的损失","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":72,"commentSize":12,"repostSize":1,"link":"https://laohu8.com/post/697545586","isVote":1,"tweetType":1,"viewCount":2509,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":106745387,"gmtCreate":1620156884249,"gmtModify":1620156884249,"author":{"id":"3461771638976755","authorId":"3461771638976755","name":"Pharmyang","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3461771638976755","authorIdStr":"3461771638976755"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AVIR\">$Atea Pharmaceuticals, Inc.(AVIR)$</a>Merck宣布免费授权给印度它的抗病毒药，对ATEA是一大利空。另外，好像流通股变多了很多。","listText":"<a href=\"https://laohu8.com/S/AVIR\">$Atea Pharmaceuticals, Inc.(AVIR)$</a>Merck宣布免费授权给印度它的抗病毒药，对ATEA是一大利空。另外，好像流通股变多了很多。","text":"$Atea Pharmaceuticals, Inc.(AVIR)$Merck宣布免费授权给印度它的抗病毒药，对ATEA是一大利空。另外，好像流通股变多了很多。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/106745387","isVote":1,"tweetType":1,"viewCount":3767,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":931620354,"gmtCreate":1570726887678,"gmtModify":1704721249362,"author":{"id":"3461771638976755","authorId":"3461771638976755","name":"Pharmyang","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3461771638976755","authorIdStr":"3461771638976755"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SGMO\">$Sangamo BioSciences(SGMO)$</a>&nbsp;这货最近持续下跌，投资人不看好","listText":"<a href=\"https://laohu8.com/S/SGMO\">$Sangamo BioSciences(SGMO)$</a>&nbsp;这货最近持续下跌，投资人不看好","text":"$Sangamo BioSciences(SGMO)$ 这货最近持续下跌，投资人不看好","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/931620354","isVote":1,"tweetType":1,"viewCount":3590,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":389804,"gmtCreate":1548703039296,"gmtModify":1704788178764,"author":{"id":"3461771638976755","authorId":"3461771638976755","name":"Pharmyang","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3461771638976755","authorIdStr":"3461771638976755"},"themes":[],"htmlText":"$Sangamo BioSciences(SGMO)$估计二月份的报告会出些好结果，估计能涨涨","listText":"$Sangamo BioSciences(SGMO)$估计二月份的报告会出些好结果，估计能涨涨","text":"$Sangamo BioSciences(SGMO)$估计二月份的报告会出些好结果，估计能涨涨","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/389804","isVote":1,"tweetType":1,"viewCount":3340,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":220119,"gmtCreate":1531765177374,"gmtModify":1704896927772,"author":{"id":"3461771638976755","authorId":"3461771638976755","name":"Pharmyang","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3461771638976755","authorIdStr":"3461771638976755"},"themes":[],"htmlText":"$CRISPR Therapeutics AG(CRSP)$ crispr遭遇巨大挑战，短期内看空","listText":"$CRISPR Therapeutics AG(CRSP)$ crispr遭遇巨大挑战，短期内看空","text":"$CRISPR Therapeutics AG(CRSP)$ crispr遭遇巨大挑战，短期内看空","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/220119","isVote":1,"tweetType":1,"viewCount":3184,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":210916,"gmtCreate":1530211768262,"gmtModify":1704895801785,"author":{"id":"3461771638976755","authorId":"3461771638976755","name":"Pharmyang","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3461771638976755","authorIdStr":"3461771638976755"},"themes":[],"htmlText":"最近老虎行情刷新特别慢，个股新闻推送还停留在五月份。是我系统的问题吗?大家最近体验如何?","listText":"最近老虎行情刷新特别慢，个股新闻推送还停留在五月份。是我系统的问题吗?大家最近体验如何?","text":"最近老虎行情刷新特别慢，个股新闻推送还停留在五月份。是我系统的问题吗?大家最近体验如何?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/210916","isVote":1,"tweetType":1,"viewCount":2657,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":176442,"gmtCreate":1523304965538,"gmtModify":1704891443517,"author":{"id":"3461771638976755","authorId":"3461771638976755","name":"Pharmyang","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3461771638976755","authorIdStr":"3461771638976755"},"themes":[],"htmlText":"分析的好","listText":"分析的好","text":"分析的好","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/176442","repostId":"176100","repostType":1,"repost":{"id":176100,"gmtCreate":1523202017157,"gmtModify":1704891402100,"author":{"id":"3484536045691836","authorId":"3484536045691836","name":"科迪勒拉","avatar":"https://static.tigerbbs.com/856f04bd0b055f6769e058b1751b7600","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3484536045691836","authorIdStr":"3484536045691836"},"themes":[],"title":"CNAT： 道阻且长 行则将至","htmlText":"$Conatus Pharmaceuticals Inc.(CNAT)$ 投资中真正需要的是思考而不是参考。 ----芒格 日前，CNAT公布了POLT-HCV-SVR关键的2b临床研究数据。客观地说，我们此前从未见过如此“好坏不清“”的数据。F2-F5组的数据已显示了emricasan抗纤维化的强大疗效，这足以让股价直上青云。谁能想到F6分组的3个安慰剂患者却以100：0的比分战胜了治疗组，此离群值直接拉低了全体治疗组的成绩，导致emricasan在此项试验中未达第一端点。反馈到市场上，其股价不涨反跌也就顺理成章了。 巴菲特和达里奥告诫我们： During times of volatility, it's best to stay calm and stick to the basics. 我们期望尽早见到公司进一步的评估结果及合作伙伴诺华的意见。以下分析文字编译自SA。 摘要： CNAT因2期数据下跌，但是阳性的分组数据分析将使该项临床试验继续 。 没有F6组中对安慰剂反应的3例异常情况，整个试验将会达到该项研究的首要端点。 F3-F5组纤维化试验数据对比强烈，emricasan 治疗组取得了95%的反应，而安慰剂组的反映比例为58.3%。 另一个催化剂事件，即肝硬化伴随门静脉高压的NASH患者身上进行的ENCORE-PH 2b试验预计在今年下半年公布数据。 财务状况良好，因CANT有足够的现金储备可坚持到2019年末，这意味着没有短期股权稀释风险。 日前，CNAT公布了POLT-HCV-SVR2b的临床研究结果。在仔细分析这些数据后，我必须说的是它们在药效方面属于中性，中性的意思是它们既非彻底的失败亦非巨大的成功。我要说的是，根据现有的结果分析，CNAT有能力将F3与F5之间纤维化分组病患人群的试验推进到3期。这是第一次有一款药物在此病患人群中显示了抗纤维化疗效。因","listText":"$Conatus Pharmaceuticals Inc.(CNAT)$ 投资中真正需要的是思考而不是参考。 ----芒格 日前，CNAT公布了POLT-HCV-SVR关键的2b临床研究数据。客观地说，我们此前从未见过如此“好坏不清“”的数据。F2-F5组的数据已显示了emricasan抗纤维化的强大疗效，这足以让股价直上青云。谁能想到F6分组的3个安慰剂患者却以100：0的比分战胜了治疗组，此离群值直接拉低了全体治疗组的成绩，导致emricasan在此项试验中未达第一端点。反馈到市场上，其股价不涨反跌也就顺理成章了。 巴菲特和达里奥告诫我们： During times of volatility, it's best to stay calm and stick to the basics. 我们期望尽早见到公司进一步的评估结果及合作伙伴诺华的意见。以下分析文字编译自SA。 摘要： CNAT因2期数据下跌，但是阳性的分组数据分析将使该项临床试验继续 。 没有F6组中对安慰剂反应的3例异常情况，整个试验将会达到该项研究的首要端点。 F3-F5组纤维化试验数据对比强烈，emricasan 治疗组取得了95%的反应，而安慰剂组的反映比例为58.3%。 另一个催化剂事件，即肝硬化伴随门静脉高压的NASH患者身上进行的ENCORE-PH 2b试验预计在今年下半年公布数据。 财务状况良好，因CANT有足够的现金储备可坚持到2019年末，这意味着没有短期股权稀释风险。 日前，CNAT公布了POLT-HCV-SVR2b的临床研究结果。在仔细分析这些数据后，我必须说的是它们在药效方面属于中性，中性的意思是它们既非彻底的失败亦非巨大的成功。我要说的是，根据现有的结果分析，CNAT有能力将F3与F5之间纤维化分组病患人群的试验推进到3期。这是第一次有一款药物在此病患人群中显示了抗纤维化疗效。因","text":"$Conatus Pharmaceuticals Inc.(CNAT)$ 投资中真正需要的是思考而不是参考。 ----芒格 日前，CNAT公布了POLT-HCV-SVR关键的2b临床研究数据。客观地说，我们此前从未见过如此“好坏不清“”的数据。F2-F5组的数据已显示了emricasan抗纤维化的强大疗效，这足以让股价直上青云。谁能想到F6分组的3个安慰剂患者却以100：0的比分战胜了治疗组，此离群值直接拉低了全体治疗组的成绩，导致emricasan在此项试验中未达第一端点。反馈到市场上，其股价不涨反跌也就顺理成章了。 巴菲特和达里奥告诫我们： During times of volatility, it's best to stay calm and stick to the basics. 我们期望尽早见到公司进一步的评估结果及合作伙伴诺华的意见。以下分析文字编译自SA。 摘要： CNAT因2期数据下跌，但是阳性的分组数据分析将使该项临床试验继续 。 没有F6组中对安慰剂反应的3例异常情况，整个试验将会达到该项研究的首要端点。 F3-F5组纤维化试验数据对比强烈，emricasan 治疗组取得了95%的反应，而安慰剂组的反映比例为58.3%。 另一个催化剂事件，即肝硬化伴随门静脉高压的NASH患者身上进行的ENCORE-PH 2b试验预计在今年下半年公布数据。 财务状况良好，因CANT有足够的现金储备可坚持到2019年末，这意味着没有短期股权稀释风险。 日前，CNAT公布了POLT-HCV-SVR2b的临床研究结果。在仔细分析这些数据后，我必须说的是它们在药效方面属于中性，中性的意思是它们既非彻底的失败亦非巨大的成功。我要说的是，根据现有的结果分析，CNAT有能力将F3与F5之间纤维化分组病患人群的试验推进到3期。这是第一次有一款药物在此病患人群中显示了抗纤维化疗效。因","images":[{"img":"https://static.laohu8.com/346fb885397b85b6724c7bd8e637f273"}],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/176100","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":3018,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":160642,"gmtCreate":1518802087118,"gmtModify":1704889453203,"author":{"id":"3461771638976755","authorId":"3461771638976755","name":"Pharmyang","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3461771638976755","authorIdStr":"3461771638976755"},"themes":[],"htmlText":"$Eyenovia Inc.(EYEN)$这股成交量可真惨淡","listText":"$Eyenovia Inc.(EYEN)$这股成交量可真惨淡","text":"$Eyenovia Inc.(EYEN)$这股成交量可真惨淡","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/160642","isVote":1,"tweetType":1,"viewCount":4402,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":122471,"gmtCreate":1511808592661,"gmtModify":1704884670132,"author":{"id":"3461771638976755","authorId":"3461771638976755","name":"Pharmyang","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3461771638976755","authorIdStr":"3461771638976755"},"themes":[],"title":"这股最近强势反弹，看来有翻身的机会了","htmlText":"$Northwest Biotherapeutics(NWBO)$这股最近强势反弹，看来有翻身的机会了","listText":"$Northwest Biotherapeutics(NWBO)$这股最近强势反弹，看来有翻身的机会了","text":"$Northwest Biotherapeutics(NWBO)$这股最近强势反弹，看来有翻身的机会了","images":[],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/122471","isVote":1,"tweetType":1,"viewCount":3763,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":99141,"gmtCreate":1506616799422,"gmtModify":1704881726365,"author":{"id":"3461771638976755","authorId":"3461771638976755","name":"Pharmyang","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3461771638976755","authorIdStr":"3461771638976755"},"themes":[],"title":"看好产品线，应该会涨起来","htmlText":"$Deciphera Pharmaceuticals Inc.(DCPH)$新股发行第一帖，果断入手1000股，早晚能涨起来","listText":"$Deciphera Pharmaceuticals Inc.(DCPH)$新股发行第一帖，果断入手1000股，早晚能涨起来","text":"$Deciphera Pharmaceuticals Inc.(DCPH)$新股发行第一帖，果断入手1000股，早晚能涨起来","images":[],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":1,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/99141","isVote":1,"tweetType":1,"viewCount":3874,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":88350,"gmtCreate":1503491946927,"gmtModify":1704880520906,"author":{"id":"3461771638976755","authorId":"3461771638976755","name":"Pharmyang","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3461771638976755","authorIdStr":"3461771638976755"},"themes":[],"title":"有收购传闻，要上吗？","htmlText":"$Paratek Pharmaceuticals Inc.(PRTK)$盘前暴涨","listText":"$Paratek Pharmaceuticals Inc.(PRTK)$盘前暴涨","text":"$Paratek Pharmaceuticals Inc.(PRTK)$盘前暴涨","images":[],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/88350","isVote":1,"tweetType":1,"viewCount":4057,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":78976,"gmtCreate":1501276439067,"gmtModify":1704879382175,"author":{"id":"3461771638976755","authorId":"3461771638976755","name":"Pharmyang","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3461771638976755","authorIdStr":"3461771638976755"},"themes":[],"htmlText":"$德纳维制药(DVAX)$乙肝疫苗终于被认可了，投票11:1 推荐，果断买入，15.7-16.0入手，下周开盘还会继续大涨","listText":"$德纳维制药(DVAX)$乙肝疫苗终于被认可了，投票11:1 推荐，果断买入，15.7-16.0入手，下周开盘还会继续大涨","text":"$德纳维制药(DVAX)$乙肝疫苗终于被认可了，投票11:1 推荐，果断买入，15.7-16.0入手，下周开盘还会继续大涨","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/78976","isVote":1,"tweetType":1,"viewCount":2480,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"302257975270708","authorId":"302257975270708","name":"空空得只隼","avatar":"https://static.tigerbbs.com/8981b04da1c29d39ebbc436041bb1c08","crmLevel":9,"crmLevelSwitch":0,"idStr":"302257975270708","authorIdStr":"302257975270708"},"content":"不理解，乙肝疫苗不是什么新药物吧，在中国随便可以打这个疫苗","text":"不理解，乙肝疫苗不是什么新药物吧，在中国随便可以打这个疫苗","html":"不理解，乙肝疫苗不是什么新药物吧，在中国随便可以打这个疫苗"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":77877,"gmtCreate":1501102121654,"gmtModify":1704879242702,"author":{"id":"3461771638976755","authorId":"3461771638976755","name":"Pharmyang","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3461771638976755","authorIdStr":"3461771638976755"},"themes":[],"htmlText":"$Intellipharmaceutics Internation(IPCI)$FDA拒了","listText":"$Intellipharmaceutics Internation(IPCI)$FDA拒了","text":"$Intellipharmaceutics Internation(IPCI)$FDA拒了","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/77877","isVote":1,"tweetType":1,"viewCount":2403,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":76098,"gmtCreate":1500580287658,"gmtModify":1704879036195,"author":{"id":"3461771638976755","authorId":"3461771638976755","name":"Pharmyang","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3461771638976755","authorIdStr":"3461771638976755"},"themes":[],"htmlText":"$Kala Pharmaceuticals Inc.(KALA)$继续打新股， 好的公司打新还是相当安全的","listText":"$Kala Pharmaceuticals Inc.(KALA)$继续打新股， 好的公司打新还是相当安全的","text":"$Kala Pharmaceuticals Inc.(KALA)$继续打新股， 好的公司打新还是相当安全的","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/76098","isVote":1,"tweetType":1,"viewCount":4317,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3463690403474527","authorId":"3463690403474527","name":"_HR_","avatar":"https://static.laohu8.com/dd9ec9fefb0df3ebcdfeb2d3a050b8b3","crmLevel":1,"crmLevelSwitch":0,"idStr":"3463690403474527","authorIdStr":"3463690403474527"},"content":"周一还适合入吗？","text":"周一还适合入吗？","html":"周一还适合入吗？"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":74381,"gmtCreate":1500027227481,"gmtModify":1704878817398,"author":{"id":"3461771638976755","authorId":"3461771638976755","name":"Pharmyang","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3461771638976755","authorIdStr":"3461771638976755"},"themes":[],"htmlText":"$Portola Pharmaceuticals Inc.(PTLA)$这股自从拿到批件暴涨后还在慢慢涨，长期看好啊","listText":"$Portola Pharmaceuticals Inc.(PTLA)$这股自从拿到批件暴涨后还在慢慢涨，长期看好啊","text":"$Portola Pharmaceuticals Inc.(PTLA)$这股自从拿到批件暴涨后还在慢慢涨，长期看好啊","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/74381","isVote":1,"tweetType":1,"viewCount":2994,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":72964,"gmtCreate":1499449538279,"gmtModify":1704878638524,"author":{"id":"3461771638976755","authorId":"3461771638976755","name":"Pharmyang","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3461771638976755","authorIdStr":"3461771638976755"},"themes":[],"htmlText":"$Pieris Pharmaceuticals, Inc.(PIRS)$ 趋势不错，长期看好","listText":"$Pieris Pharmaceuticals, Inc.(PIRS)$ 趋势不错，长期看好","text":"$Pieris Pharmaceuticals, Inc.(PIRS)$ 趋势不错，长期看好","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/72964","isVote":1,"tweetType":1,"viewCount":2542,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":697545586,"gmtCreate":1642543473616,"gmtModify":1642543473616,"author":{"id":"3461771638976755","authorId":"3461771638976755","name":"Pharmyang","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3461771638976755","authorIdStr":"3461771638976755"},"themes":[],"htmlText":"‌<a href=\"https://laohu8.com/S/RIVN\">$Rivian Automotive, Inc.(RIVN)$</a>‌上周买了82的put，1.21到期，希望它继续跌，弥补我在 $Tesla$&nbsp;call 上的损失","listText":"‌<a href=\"https://laohu8.com/S/RIVN\">$Rivian Automotive, Inc.(RIVN)$</a>‌上周买了82的put，1.21到期，希望它继续跌，弥补我在 $Tesla$&nbsp;call 上的损失","text":"‌$Rivian Automotive, Inc.(RIVN)$‌上周买了82的put，1.21到期，希望它继续跌，弥补我在 $Tesla$ call 上的损失","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":72,"commentSize":12,"repostSize":1,"link":"https://laohu8.com/post/697545586","isVote":1,"tweetType":1,"viewCount":2509,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":78976,"gmtCreate":1501276439067,"gmtModify":1704879382175,"author":{"id":"3461771638976755","authorId":"3461771638976755","name":"Pharmyang","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3461771638976755","authorIdStr":"3461771638976755"},"themes":[],"htmlText":"$德纳维制药(DVAX)$乙肝疫苗终于被认可了，投票11:1 推荐，果断买入，15.7-16.0入手，下周开盘还会继续大涨","listText":"$德纳维制药(DVAX)$乙肝疫苗终于被认可了，投票11:1 推荐，果断买入，15.7-16.0入手，下周开盘还会继续大涨","text":"$德纳维制药(DVAX)$乙肝疫苗终于被认可了，投票11:1 推荐，果断买入，15.7-16.0入手，下周开盘还会继续大涨","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/78976","isVote":1,"tweetType":1,"viewCount":2480,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"302257975270708","authorId":"302257975270708","name":"空空得只隼","avatar":"https://static.tigerbbs.com/8981b04da1c29d39ebbc436041bb1c08","crmLevel":9,"crmLevelSwitch":0,"idStr":"302257975270708","authorIdStr":"302257975270708"},"content":"不理解，乙肝疫苗不是什么新药物吧，在中国随便可以打这个疫苗","text":"不理解，乙肝疫苗不是什么新药物吧，在中国随便可以打这个疫苗","html":"不理解，乙肝疫苗不是什么新药物吧，在中国随便可以打这个疫苗"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":99141,"gmtCreate":1506616799422,"gmtModify":1704881726365,"author":{"id":"3461771638976755","authorId":"3461771638976755","name":"Pharmyang","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3461771638976755","authorIdStr":"3461771638976755"},"themes":[],"title":"看好产品线，应该会涨起来","htmlText":"$Deciphera Pharmaceuticals Inc.(DCPH)$新股发行第一帖，果断入手1000股，早晚能涨起来","listText":"$Deciphera Pharmaceuticals Inc.(DCPH)$新股发行第一帖，果断入手1000股，早晚能涨起来","text":"$Deciphera Pharmaceuticals Inc.(DCPH)$新股发行第一帖，果断入手1000股，早晚能涨起来","images":[],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":1,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/99141","isVote":1,"tweetType":1,"viewCount":3874,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":76098,"gmtCreate":1500580287658,"gmtModify":1704879036195,"author":{"id":"3461771638976755","authorId":"3461771638976755","name":"Pharmyang","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3461771638976755","authorIdStr":"3461771638976755"},"themes":[],"htmlText":"$Kala Pharmaceuticals Inc.(KALA)$继续打新股， 好的公司打新还是相当安全的","listText":"$Kala Pharmaceuticals Inc.(KALA)$继续打新股， 好的公司打新还是相当安全的","text":"$Kala Pharmaceuticals Inc.(KALA)$继续打新股， 好的公司打新还是相当安全的","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/76098","isVote":1,"tweetType":1,"viewCount":4317,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3463690403474527","authorId":"3463690403474527","name":"_HR_","avatar":"https://static.laohu8.com/dd9ec9fefb0df3ebcdfeb2d3a050b8b3","crmLevel":1,"crmLevelSwitch":0,"idStr":"3463690403474527","authorIdStr":"3463690403474527"},"content":"周一还适合入吗？","text":"周一还适合入吗？","html":"周一还适合入吗？"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":931620354,"gmtCreate":1570726887678,"gmtModify":1704721249362,"author":{"id":"3461771638976755","authorId":"3461771638976755","name":"Pharmyang","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3461771638976755","authorIdStr":"3461771638976755"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SGMO\">$Sangamo BioSciences(SGMO)$</a>&nbsp;这货最近持续下跌，投资人不看好","listText":"<a href=\"https://laohu8.com/S/SGMO\">$Sangamo BioSciences(SGMO)$</a>&nbsp;这货最近持续下跌，投资人不看好","text":"$Sangamo BioSciences(SGMO)$ 这货最近持续下跌，投资人不看好","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/931620354","isVote":1,"tweetType":1,"viewCount":3590,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":72964,"gmtCreate":1499449538279,"gmtModify":1704878638524,"author":{"id":"3461771638976755","authorId":"3461771638976755","name":"Pharmyang","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3461771638976755","authorIdStr":"3461771638976755"},"themes":[],"htmlText":"$Pieris Pharmaceuticals, Inc.(PIRS)$ 趋势不错，长期看好","listText":"$Pieris Pharmaceuticals, Inc.(PIRS)$ 趋势不错，长期看好","text":"$Pieris Pharmaceuticals, Inc.(PIRS)$ 趋势不错，长期看好","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/72964","isVote":1,"tweetType":1,"viewCount":2542,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":389804,"gmtCreate":1548703039296,"gmtModify":1704788178764,"author":{"id":"3461771638976755","authorId":"3461771638976755","name":"Pharmyang","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3461771638976755","authorIdStr":"3461771638976755"},"themes":[],"htmlText":"$Sangamo BioSciences(SGMO)$估计二月份的报告会出些好结果，估计能涨涨","listText":"$Sangamo BioSciences(SGMO)$估计二月份的报告会出些好结果，估计能涨涨","text":"$Sangamo BioSciences(SGMO)$估计二月份的报告会出些好结果，估计能涨涨","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/389804","isVote":1,"tweetType":1,"viewCount":3340,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":160642,"gmtCreate":1518802087118,"gmtModify":1704889453203,"author":{"id":"3461771638976755","authorId":"3461771638976755","name":"Pharmyang","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3461771638976755","authorIdStr":"3461771638976755"},"themes":[],"htmlText":"$Eyenovia Inc.(EYEN)$这股成交量可真惨淡","listText":"$Eyenovia Inc.(EYEN)$这股成交量可真惨淡","text":"$Eyenovia Inc.(EYEN)$这股成交量可真惨淡","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/160642","isVote":1,"tweetType":1,"viewCount":4402,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":88350,"gmtCreate":1503491946927,"gmtModify":1704880520906,"author":{"id":"3461771638976755","authorId":"3461771638976755","name":"Pharmyang","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3461771638976755","authorIdStr":"3461771638976755"},"themes":[],"title":"有收购传闻，要上吗？","htmlText":"$Paratek Pharmaceuticals Inc.(PRTK)$盘前暴涨","listText":"$Paratek Pharmaceuticals Inc.(PRTK)$盘前暴涨","text":"$Paratek Pharmaceuticals Inc.(PRTK)$盘前暴涨","images":[],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/88350","isVote":1,"tweetType":1,"viewCount":4057,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":77877,"gmtCreate":1501102121654,"gmtModify":1704879242702,"author":{"id":"3461771638976755","authorId":"3461771638976755","name":"Pharmyang","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3461771638976755","authorIdStr":"3461771638976755"},"themes":[],"htmlText":"$Intellipharmaceutics Internation(IPCI)$FDA拒了","listText":"$Intellipharmaceutics Internation(IPCI)$FDA拒了","text":"$Intellipharmaceutics Internation(IPCI)$FDA拒了","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/77877","isVote":1,"tweetType":1,"viewCount":2403,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":220119,"gmtCreate":1531765177374,"gmtModify":1704896927772,"author":{"id":"3461771638976755","authorId":"3461771638976755","name":"Pharmyang","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3461771638976755","authorIdStr":"3461771638976755"},"themes":[],"htmlText":"$CRISPR Therapeutics AG(CRSP)$ crispr遭遇巨大挑战，短期内看空","listText":"$CRISPR Therapeutics AG(CRSP)$ crispr遭遇巨大挑战，短期内看空","text":"$CRISPR Therapeutics AG(CRSP)$ crispr遭遇巨大挑战，短期内看空","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/220119","isVote":1,"tweetType":1,"viewCount":3184,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":106745387,"gmtCreate":1620156884249,"gmtModify":1620156884249,"author":{"id":"3461771638976755","authorId":"3461771638976755","name":"Pharmyang","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3461771638976755","authorIdStr":"3461771638976755"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AVIR\">$Atea Pharmaceuticals, Inc.(AVIR)$</a>Merck宣布免费授权给印度它的抗病毒药，对ATEA是一大利空。另外，好像流通股变多了很多。","listText":"<a href=\"https://laohu8.com/S/AVIR\">$Atea Pharmaceuticals, Inc.(AVIR)$</a>Merck宣布免费授权给印度它的抗病毒药，对ATEA是一大利空。另外，好像流通股变多了很多。","text":"$Atea Pharmaceuticals, Inc.(AVIR)$Merck宣布免费授权给印度它的抗病毒药，对ATEA是一大利空。另外，好像流通股变多了很多。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/106745387","isVote":1,"tweetType":1,"viewCount":3767,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":210916,"gmtCreate":1530211768262,"gmtModify":1704895801785,"author":{"id":"3461771638976755","authorId":"3461771638976755","name":"Pharmyang","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3461771638976755","authorIdStr":"3461771638976755"},"themes":[],"htmlText":"最近老虎行情刷新特别慢，个股新闻推送还停留在五月份。是我系统的问题吗?大家最近体验如何?","listText":"最近老虎行情刷新特别慢，个股新闻推送还停留在五月份。是我系统的问题吗?大家最近体验如何?","text":"最近老虎行情刷新特别慢，个股新闻推送还停留在五月份。是我系统的问题吗?大家最近体验如何?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/210916","isVote":1,"tweetType":1,"viewCount":2657,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":176442,"gmtCreate":1523304965538,"gmtModify":1704891443517,"author":{"id":"3461771638976755","authorId":"3461771638976755","name":"Pharmyang","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3461771638976755","authorIdStr":"3461771638976755"},"themes":[],"htmlText":"分析的好","listText":"分析的好","text":"分析的好","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/176442","repostId":"176100","repostType":1,"repost":{"id":176100,"gmtCreate":1523202017157,"gmtModify":1704891402100,"author":{"id":"3484536045691836","authorId":"3484536045691836","name":"科迪勒拉","avatar":"https://static.tigerbbs.com/856f04bd0b055f6769e058b1751b7600","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3484536045691836","authorIdStr":"3484536045691836"},"themes":[],"title":"CNAT： 道阻且长 行则将至","htmlText":"$Conatus Pharmaceuticals Inc.(CNAT)$ 投资中真正需要的是思考而不是参考。 ----芒格 日前，CNAT公布了POLT-HCV-SVR关键的2b临床研究数据。客观地说，我们此前从未见过如此“好坏不清“”的数据。F2-F5组的数据已显示了emricasan抗纤维化的强大疗效，这足以让股价直上青云。谁能想到F6分组的3个安慰剂患者却以100：0的比分战胜了治疗组，此离群值直接拉低了全体治疗组的成绩，导致emricasan在此项试验中未达第一端点。反馈到市场上，其股价不涨反跌也就顺理成章了。 巴菲特和达里奥告诫我们： During times of volatility, it's best to stay calm and stick to the basics. 我们期望尽早见到公司进一步的评估结果及合作伙伴诺华的意见。以下分析文字编译自SA。 摘要： CNAT因2期数据下跌，但是阳性的分组数据分析将使该项临床试验继续 。 没有F6组中对安慰剂反应的3例异常情况，整个试验将会达到该项研究的首要端点。 F3-F5组纤维化试验数据对比强烈，emricasan 治疗组取得了95%的反应，而安慰剂组的反映比例为58.3%。 另一个催化剂事件，即肝硬化伴随门静脉高压的NASH患者身上进行的ENCORE-PH 2b试验预计在今年下半年公布数据。 财务状况良好，因CANT有足够的现金储备可坚持到2019年末，这意味着没有短期股权稀释风险。 日前，CNAT公布了POLT-HCV-SVR2b的临床研究结果。在仔细分析这些数据后，我必须说的是它们在药效方面属于中性，中性的意思是它们既非彻底的失败亦非巨大的成功。我要说的是，根据现有的结果分析，CNAT有能力将F3与F5之间纤维化分组病患人群的试验推进到3期。这是第一次有一款药物在此病患人群中显示了抗纤维化疗效。因","listText":"$Conatus Pharmaceuticals Inc.(CNAT)$ 投资中真正需要的是思考而不是参考。 ----芒格 日前，CNAT公布了POLT-HCV-SVR关键的2b临床研究数据。客观地说，我们此前从未见过如此“好坏不清“”的数据。F2-F5组的数据已显示了emricasan抗纤维化的强大疗效，这足以让股价直上青云。谁能想到F6分组的3个安慰剂患者却以100：0的比分战胜了治疗组，此离群值直接拉低了全体治疗组的成绩，导致emricasan在此项试验中未达第一端点。反馈到市场上，其股价不涨反跌也就顺理成章了。 巴菲特和达里奥告诫我们： During times of volatility, it's best to stay calm and stick to the basics. 我们期望尽早见到公司进一步的评估结果及合作伙伴诺华的意见。以下分析文字编译自SA。 摘要： CNAT因2期数据下跌，但是阳性的分组数据分析将使该项临床试验继续 。 没有F6组中对安慰剂反应的3例异常情况，整个试验将会达到该项研究的首要端点。 F3-F5组纤维化试验数据对比强烈，emricasan 治疗组取得了95%的反应，而安慰剂组的反映比例为58.3%。 另一个催化剂事件，即肝硬化伴随门静脉高压的NASH患者身上进行的ENCORE-PH 2b试验预计在今年下半年公布数据。 财务状况良好，因CANT有足够的现金储备可坚持到2019年末，这意味着没有短期股权稀释风险。 日前，CNAT公布了POLT-HCV-SVR2b的临床研究结果。在仔细分析这些数据后，我必须说的是它们在药效方面属于中性，中性的意思是它们既非彻底的失败亦非巨大的成功。我要说的是，根据现有的结果分析，CNAT有能力将F3与F5之间纤维化分组病患人群的试验推进到3期。这是第一次有一款药物在此病患人群中显示了抗纤维化疗效。因","text":"$Conatus Pharmaceuticals Inc.(CNAT)$ 投资中真正需要的是思考而不是参考。 ----芒格 日前，CNAT公布了POLT-HCV-SVR关键的2b临床研究数据。客观地说，我们此前从未见过如此“好坏不清“”的数据。F2-F5组的数据已显示了emricasan抗纤维化的强大疗效，这足以让股价直上青云。谁能想到F6分组的3个安慰剂患者却以100：0的比分战胜了治疗组，此离群值直接拉低了全体治疗组的成绩，导致emricasan在此项试验中未达第一端点。反馈到市场上，其股价不涨反跌也就顺理成章了。 巴菲特和达里奥告诫我们： During times of volatility, it's best to stay calm and stick to the basics. 我们期望尽早见到公司进一步的评估结果及合作伙伴诺华的意见。以下分析文字编译自SA。 摘要： CNAT因2期数据下跌，但是阳性的分组数据分析将使该项临床试验继续 。 没有F6组中对安慰剂反应的3例异常情况，整个试验将会达到该项研究的首要端点。 F3-F5组纤维化试验数据对比强烈，emricasan 治疗组取得了95%的反应，而安慰剂组的反映比例为58.3%。 另一个催化剂事件，即肝硬化伴随门静脉高压的NASH患者身上进行的ENCORE-PH 2b试验预计在今年下半年公布数据。 财务状况良好，因CANT有足够的现金储备可坚持到2019年末，这意味着没有短期股权稀释风险。 日前，CNAT公布了POLT-HCV-SVR2b的临床研究结果。在仔细分析这些数据后，我必须说的是它们在药效方面属于中性，中性的意思是它们既非彻底的失败亦非巨大的成功。我要说的是，根据现有的结果分析，CNAT有能力将F3与F5之间纤维化分组病患人群的试验推进到3期。这是第一次有一款药物在此病患人群中显示了抗纤维化疗效。因","images":[{"img":"https://static.laohu8.com/346fb885397b85b6724c7bd8e637f273"}],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/176100","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":3018,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":122471,"gmtCreate":1511808592661,"gmtModify":1704884670132,"author":{"id":"3461771638976755","authorId":"3461771638976755","name":"Pharmyang","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3461771638976755","authorIdStr":"3461771638976755"},"themes":[],"title":"这股最近强势反弹，看来有翻身的机会了","htmlText":"$Northwest Biotherapeutics(NWBO)$这股最近强势反弹，看来有翻身的机会了","listText":"$Northwest Biotherapeutics(NWBO)$这股最近强势反弹，看来有翻身的机会了","text":"$Northwest Biotherapeutics(NWBO)$这股最近强势反弹，看来有翻身的机会了","images":[],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/122471","isVote":1,"tweetType":1,"viewCount":3763,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":74381,"gmtCreate":1500027227481,"gmtModify":1704878817398,"author":{"id":"3461771638976755","authorId":"3461771638976755","name":"Pharmyang","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3461771638976755","authorIdStr":"3461771638976755"},"themes":[],"htmlText":"$Portola Pharmaceuticals Inc.(PTLA)$这股自从拿到批件暴涨后还在慢慢涨，长期看好啊","listText":"$Portola Pharmaceuticals Inc.(PTLA)$这股自从拿到批件暴涨后还在慢慢涨，长期看好啊","text":"$Portola Pharmaceuticals Inc.(PTLA)$这股自从拿到批件暴涨后还在慢慢涨，长期看好啊","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/74381","isVote":1,"tweetType":1,"viewCount":2994,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}